Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A CRL citing manufacturing, not efficacy put phase-3 protocol with endpoint-sensitivity issues in front of CMC change-control owner in a labeling team facing a boxed-warning debate. This Pharma & Life Sciences / FDA Response and Labeling close is to drop a secondary from phase-3 protocol with endpoint-sensitivity issues, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION CMC change-control owner in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. The population in phase-3 protocol with endpoint-sensitivity issues is the one a CRL citing manufacturing, not efficacy named, so Proceed under protocol follows for this FDA Response and Labeling file. 2. The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a CRL citing manufacturing, not efficacy; Pause the pathway is the honest Pharma & Life Sciences call. 3. A labeling team facing a boxed-warning debate already contained a CRL citing manufacturing, not efficacy before phase-3 protocol with endpoint-sensitivity issues arrived; no new FDA Response and Labeling path. 4. Provenance on phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for CMC change-control owner in a labeling team facing a boxed-warning debate.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in phase-3 protocol with endpoint-sensitivity issues, then the action for CMC change-control owner - Hypothesis scorecard against phase-3 protocol with endpoint-sensitivity issues: supported / rejected / untestable - Missing page in phase-3 protocol with endpoint-sensitivity issues after a CRL citing manufacturing, not efficacy, if any - Regulatory or exam hook FDA Response and Labeling would cite